17,261 trials
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose-limiting Toxicities Due to Romidepsin Graded According to the NCI Common Toxicity Criteria (CTCAE Version 3.0) (Phase I) — 0 participants
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) After Morning Study Drug Administration at…
Prostate Cancer
Primary: Gene Expression of Phase II Enzymes — -0.36; 0.26; 0.15; -0.59 -fold change in expression
Esophageal Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Dengue · Dengue Hemorrhagic Fever
Primary: Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine…
Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: Safety and Toxicity as Measured by Treatment Related Non-hematologic Adverse Events — 34; 6; 7; 3 participants
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 — 73.2; 65.5; 76.8; 81.8 percentage of participants — p==0.863
Childhood CNS Primitive Neuroectodermal Tumor
Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants
Metastatic Cancer · Prostate Cancer
Primary: Progression Free Survival (PFS) — 12.9; 18.5 Months
Low Grade Astrocytomas
Primary: Number of Participants With Objective Response — 4; 1; 4; 0 Participants
Bone Metastases · Castration-Resistant Prostate Cancer
Primary: Number of Subjects With Dose-Limiting Toxicities - Dose Escalation Part — 0; 0; 0 Participants
Colorectal Cancer
Primary: Tumour Response — 0; 0 Percentage of Participants
Rectal Cancer
Primary: Percentage of Participants With Pathological Complete Tumor Response — 23 Percentage of participants
Congenital Hyperinsulinism
Primary: Mean Blood Glucose Area Under the Curve (AUC 0-6h) — 2,096; 1,678 mmol*min/L
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12) — 0.187; 0.189; 0.144; 0.114 Liters…